NCT06831032 Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response
| NCT ID | NCT06831032 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Prostate Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2026-07-07 |
| Primary Completion | 2029-07-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 26 participants in total. It began in 2026-07-07 with a primary completion date of 2029-07-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, single-arm feasibility study will include patients with prostate cancer that have controlled local disease diagnosed with oligorecurrent para-aortic nodal disease and/or common iliac nodal disease detected by PSMA PET or conventional CT/MRI imaging, and these patients will undergo CT-guided online adaptive SBRT to the tumor and elective SBRT to adjacent at-risk nodal regions.
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed prostate adenocarcinoma. 2. Oligorecurrent para-aortic +/- common iliac nodal disease planned for SBRT. 3. ≤10 involved para-aortic (defined as between L1/L2 interface and L4/L5 interface) +/- common iliac LN on PSMA PET imaging. 4. ECOG performance status 0-2. Exclusion Criteria: 1. Prior radiotherapy to the nodal echelon (PA +/- common iliac). 2. Active secondary malignancy, except for adequately treated non-melanoma skin cancer. 3. Presence of significant comorbidities or medical conditions that may compromise the ability to undergo radiotherapy or participate in the study. 4. Contraindication to radiation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06831032 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06831032 currently recruiting?
Yes, NCT06831032 is actively recruiting participants. Contact the research team at andrew.mcpartlin@uhn.ca for enrollment information.
Where is the NCT06831032 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06831032 clinical trial?
NCT06831032 is sponsored by University Health Network, Toronto. The trial plans to enroll 26 participants.